Low-Dose Rosiglitazone in Patients With Insulin-Requiring Type 2 Diabetes

Abstract

Background: The objective was to compare the efficacy and safety of adding low-dose rosiglitazone (2 or 4 mg/d) to insulin therapy vs continued insulin monotherapy in patients with type 2 diabetes mellitus who were unable to achieve glycemic control with insulin therapy alone. Methods: In this 24-week, double-blind study, 630 individuals with type 2 diabetes mellitus that was inadequately controlled with insulin therapy alone were randomized to treatment with rosiglitazone (2 or 4 mg/d) or placebo in combination with ongoing insulin therapy. The dosage of insulin therapy could be adjusted at the investigator's discretion if required for hypoglycemia or additional glycemic control. Results: The addition of rosiglitazone (2 or 4 mg/d) to insulin therapy significantly decreased mean glycated hemoglobin concentrations compared with placebo plus insulin (-0.3% [P = .

Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes

“…Decreased glycosuria may play a role, but these drugs appear to also have a direct effect on the PPAR receptors on the adipocyte and thus stimulate adipogenesis. Hollander et al 37 saw a lesser weight gain of 7.0 lb in a 6-month study of 4 mg of rosiglitazone in patients on insulin therapy; A1C decreased 0.4% from a baseline of 8.5%. Flux in fluid balance may also occur in patients, as signified by peripheral edema.…”

Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus

“…Twenty-nine RCTs (18 with rosiglitazone [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43] and 11 with pioglitazone [44][45][46][47][48][49][50][51][52][53][54] ) were included for the final analyses (see table I). Twenty-nine RCTs (18 with rosiglitazone [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43] and 11 with pioglitazone [44][45][46]…”

Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses

“…When used in combination with insulin, these agents have had a modest insulin sparing effect (mean decrease 9% or 13 IU/d) (20 -28) and improved glycemic control, compared with placebo (20,22,23,26). Because of fear of hepatotoxicity after withdrawal of troglitazone due to idiosyncratic liver reactions, patients with elevated liver enzymes were carefully excluded from these studies (21)(22)(23)(24)(25)28).…”